Why the study?
Does dibutyryl cyclic AMP reduce ventricular vulnerability in dogs with complete atrioventricular block?
Does dibutyryl cyclic AMP reduce ventricular vulnerability in dogs with complete atrioventricular block?
DBcAMP exhibits suppressive effects on ventricular vulnerability in an experimental dog model of complete atrioventricular block.
Hypothesis-generating for DBcAMP in ventricular arrhythmia models; leaves open translation to human clinical practice.
The effects of dibutyryl cyclic AMP (DBcAMP) on ventricular vulnerability during complete atrioventricular block (CAVB) were studied one week after transarterial electrical ablation of the AV junction in 18 closed-chest dogs. All dogs exhibited CAVB and a stable ventricular escape rhythm with a mean cycle length of 1812 +/- 638 ms. After the administration of DBcAMP at a rate of 0.1 mg/kg/min for 30 min, the ventricular cycle length was significantly shortened, and the QTc interval was slightly prolonged, although the QT interval did not change. The ventricular fibrillation threshold after the administration of DBcAMP was significantly increased (from 12.2 +/- 3 84 to 18.4 +/- 5.08 mA, p less than 0.01). Thus, it was demonstrated that DBcAMP exhibited suppressive effects on the ventricular vulnerability in the experimentally induced CAVB.
No takes yet. Share an insight, caveat, or question.
Kumagai et al. (1991) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: